Press release Communiqué de presse
Press release Communiqué de presse
May 24, 2022 24 May, 2022
Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange
London, Ontario – May 24, 2022 – Sernova Corp. (TSX-V:SVA; OTCQB:SEOVF; FSE/XETRA:PSH), a clinical-
stage company and leader in regenerative medicine cell therapeutics, is pleased to announce that it has
received conditional approval to list its common shares on the Toronto Stock Exchange (the "TSX") and move
off of the TSX Venture Exchange ("TSXV").
Final approval of the listing is subject to the Company meeting certain customary conditions required by the
TSX. The company will issue a press release once the TSX confirms the date when trading of Sernova’s
common shares is expected to commence on the TSX. Upon completion of the final listing requirements,
Sernova’s common shares will be delisted from the TSXV.
Dr. Philip Toleikis, President and CEO of Sernova Corp commented, “Moving onto the Toronto Stock Exchange
represents a milestone achievement in our evolution as an emerging regenerative medicine company. Up-
listing will provide enhanced liquidity and bring new visibility and investors into the company as we advance
our therapeutic cell therapy platform with the goal to provide ‘functional cures’ for multiple diseases including
type one diabetes, hemophilia and thyroid disease.”
Shareholders are not required to exchange their share certificates or take any other action in connection with
the TSX listing, as there will be no change in the trading symbol or CUSIP for the common shares. The
Company will continue to trade its common shares on the OTCQB market in the United States under the
symbol "SEOVF", and the Frankfurt exchange under the symbol "PSH".
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM™ PLATFORM FOR CELL THERAPY
Sernova Corp. is developing regenerative medicine therapeutic technologies using a medical device and
immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived
cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of
proteins or hormones missing or in short supply within the body.
The Cell Pouch™ is a proprietary, scalable, implantable macro- encapsulation device solution designed for the
long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue,
forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells,
that release proteins and hormones as required to treat disease.
The Cell Pouch along with therapeutic cells, has been shown to provide long-term safety and efficacy in small
and large animal models of diabetes and has been proven to provide a biologically compatible environment for
insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase
1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several
international scientific conferences.
For more information, please visit www.sernova.com
For further information contact:
Corporate and Investors:
Sernova Corp.
Christopher Barnes
Tel: (519) 858-5126
christopher.barnes@sernova.com
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Elizabeth Miller, MD
LifeSci Communications
emiller@lifescicomms.com
Neither the TSXV nor the TSX accepts responsibility for the adequacy or accuracy of this news release.
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on
the date such statements were made, which include our beliefs about the conduct and outcome of clinical
trials, and the development of new technologies, cell therapy solutions and or products. The information
disclosed represents results from one patient and may not be representative of all study patients or of the final
study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or otherwise.